Firazyr
Hereditary Angioedema
Nang Kuang Pharmaceutical Co., Ltd.Phase 4 / ApprovedActive
A
87/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 81/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Hereditary Angioedema cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sebetralstat KalVista Pharmaceuticals, Ltd. | Phase 4 | A |
Berotralstat BioCryst Pharmaceuticals | Phase 3 | A |
Lanadelumab Takeda | Phase 3 | A |
Garadacimab CSL Behring | Phase 4 | BBB |
Ecallantide NYU Langone Health | Phase 3 | BBB |
View all 36 →
Same molecule, other indications
Firazyr is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →